Female Pattern Hair Loss: What's Happening and What Actually Works

Is your part widening? Are you seeing more scalp under bathroom light, or noticing your ponytail feels thinner than it did two years ago? You probably already know what this article is about, even if no one has said the words to you yet.

Female pattern hair loss (FPHL) is the most common form of hair loss in women, affecting roughly 40% by age 60¹ . The medical framing is androgenetic alopecia, the same underlying mechanism as male pattern hair loss, but the presentation, the workup, and several of the treatments are different. The emotional weight is also, for most women, considerably heavier than the medical literature acknowledges.

What FPHL looks like

FPHL is recognisable from a specific pattern, not from severity:

• Diffuse central thinning. The top of the scalp gets thinner, with the area around the part most affected.
• Widening of the part. The “Christmas tree” pattern, where the part flares out toward the front of the scalp.
• Frontal hairline preserved. Unlike male pattern hair loss, women rarely lose the front hairline.
• Sides and back relatively untouched. Your ponytail thins, but the perimeter holds.
• Slow, gradual progression. Usually over months to years, often noticed first as “my part looks bigger”.

Two scales grade severity:

• Ludwig scale: stages I–III based on how much central scalp shows through
• Sinclair scale: a 5-point visual scale based on the part width photographed from above (often used in clinical trials and easy to apply at home)

The scales matter mainly because they let you track change over time. A Sinclair 2 photo today and a Sinclair 2 photo in 12 months tells you whether treatment is working.

Why it’s happening

The underlying mechanism is the same as male pattern hair loss: hair follicles in genetically susceptible scalp regions are sensitive to androgens (especially DHT), which cause those follicles to miniaturise. The follicles produce progressively shorter, thinner hairs until the cycle eventually stops¹ .

What’s different in women:

• The androgen exposure is lower, so the loss is usually slower and more diffuse, and less likely to progress to baldness.
• Estrogen modulates the picture. Estrogen extends the anagen phase. When estrogen drops (postpartum, perimenopause, menopause), pattern hair loss often becomes apparent for the first time, even though the genetic predisposition was always there.
• Other hormonal contributions matter more often. PCOS, thyroid disease, and low ferritin all interact with FPHL and need to be considered, especially when loss is rapid or out of proportion to age.

This is why a workup matters in women in a way it doesn’t always in men: ruling out a treatable contributor (low ferritin, thyroid, PCOS) before settling on FPHL alone.

Workup: what to ask for

Standard initial blood panel for women with diffuse hair loss or suspected FPHL:

• Ferritin. Iron stores. Aim for above 50 ng/mL (some hair specialists target above 70). The most useful single test.
• TSH (and free T4 if abnormal) for thyroid function.
• Complete blood count (CBC) for anaemia and broader picture.
• Vitamin D and vitamin B12, which are common deficiencies that affect hair.
• Zinc, uncommonly low but worth checking in restrictive eaters.

For women with hair loss plus other androgen-excess symptoms (acne, irregular periods, hirsutism, weight changes), add:

• Total and free testosterone
• DHEAS
• Prolactin
• 17-hydroxyprogesterone (if congenital adrenal hyperplasia is on the differential)

We cover the panel and what the values mean in our blood tests for hair loss guide.

A dermatologist can also do trichoscopy (scalp magnification) and a pull test in the room. If the picture is unclear (diffuse loss with no obvious pattern, or rapid progression) a punch biopsy under local anaesthetic distinguishes FPHL from chronic telogen effluvium and other diffuse causes.

What actually works

There are four treatments with the strongest evidence for FPHL. Most dermatologists pick from this list, often in combination.

Topical minoxidil (FDA-approved)

The first-line treatment⁵ . Available over the counter in 2% and 5% formulations. The 5% foam (once daily) is now the most common prescribing pattern.

• Mechanism: prolongs the anagen (growth) phase; partially counteracts follicle miniaturisation.
• Dose: 1 mL twice daily (2% or 5% solution) or one cap of 5% foam once daily.
• Who it’s for: most women with FPHL, as a foundation.
• Timeline: visible change at 4–6 months, full effect at 12 months³ . The first 4–8 weeks may include a “shed”, a temporary increased loss as follicles synchronise into a new growth cycle. This is normal.
• Side effects: scalp irritation (foam better tolerated than solution), occasional unwanted facial hair from runoff.
• What stopping does: gains reverse within 3–6 months.

Full details in our minoxidil guide.

Oral spironolactone (off-label)

A potassium-sparing diuretic with anti-androgen activity at higher doses. Widely used off-label by dermatologists for FPHL, especially in women with concurrent acne or hirsutism² .

• Mechanism: blocks androgen receptors in hair follicles; modestly suppresses adrenal androgen production.
• Typical dose: 100–200 mg/day, often started lower and titrated up.
• Who it’s for: women with FPHL not adequately controlled by minoxidil alone, or with androgen-excess symptoms.
• Timeline: 6–12 months for visible effect.
• Side effects: menstrual irregularity, breast tenderness, lightheadedness; risk of high potassium (rare but worth a baseline check). Pregnancy is a hard contraindication, since spironolactone can cause feminisation of male fetuses.
• What stopping does: gains reverse over months.

Low-dose oral minoxidil (off-label)

In the last few years, low-dose oral minoxidil (LDOM) has become a common addition or alternative to topical minoxidil for FPHL⁴ .

• Typical dose: 0.625–2.5 mg/day for women (lower than the male protocol).
• Mechanism: same as topical, but systemic.
• Who it’s for: women who can’t tolerate topical (irritation, adherence), or who want better effect than topical alone.
• Timeline: 3–6 months for visible change.
• Side effects: hypertrichosis (extra body and facial hair) is the most common, dose-dependent. Fluid retention and lightheadedness are possible. Cardiovascular screening and ongoing monitoring are appropriate.
• What stopping does: gains reverse.

Oral finasteride (off-label, controversial)

Finasteride is FDA-approved for male AGA but used off-label for FPHL in some clinics, more often in postmenopausal women.

• Mechanism: 5α-reductase inhibition, reducing DHT.
• Evidence in FPHL: mixed. Some trials show benefit at higher doses (5 mg/day), particularly in postmenopausal women; others find no significant effect. Less reliable than spironolactone or minoxidil.
• Hard contraindication: pregnancy. Finasteride causes severe birth defects in male fetuses; women of reproductive age should not take it without strict contraception.

A more aggressive 5α-reductase inhibitor, dutasteride, is also occasionally used off-label. We cover both in our finasteride vs. dutasteride guide.

What doesn’t help (much)

A few things are widely sold and widely useless:

• Most “hair growth” supplements. No supplement has demonstrated meaningful efficacy in randomised trials for FPHL in well-nourished women. Targeted supplementation for actual deficiencies (iron, vitamin D, B12) does help. Generic multivitamin-marketed-as-hair-fix does not.
• Biotin. Helps only in the rare case of true biotin deficiency. Routine high-dose biotin can also interfere with thyroid blood tests, which matters because thyroid is part of the FPHL workup.
• Caffeine shampoos and similar topical cosmetics. No clinical evidence at the level of minoxidil.
• PRP for FPHL. Mixed evidence; the trials are small and inconsistent. Some women see benefit; the cost-to-evidence ratio is unfavourable compared to minoxidil + spironolactone.
• Most “hair clinic” proprietary blends. If they had RCT-level evidence, they’d be FDA-approved.

A realistic plan, in order

1. Get a baseline. Photograph your scalp from above (Sinclair-style) under consistent lighting. You’ll want this to track progress.
2. Get bloods. Ferritin, TSH, CBC, vitamin D, B12, zinc; add a hormonal panel if you have androgen-excess symptoms. Treat any actual deficiencies.
3. Start topical 5% minoxidil if FPHL is confirmed or strongly suspected. Commit for 6–12 months before judging.
4. See a dermatologist if loss is rapid, if the picture is unclear, or if you want to add spironolactone, oral minoxidil, or finasteride.
5. Re-photograph at 6 and 12 months. Track Sinclair stage and part width over the same lighting/angle. Whether to escalate or maintain depends on the trajectory.

When to see a dermatologist

• Rapid or severe loss (especially with other symptoms)
• Loss that doesn’t fit the FPHL pattern (sharply-bordered patches, scalp redness/scaling/itching, hairline recession)
• You want to consider spironolactone, oral minoxidil, or finasteride
• 6+ months of topical minoxidil with no apparent response
• You’re trying to conceive, are pregnant, or are breastfeeding, since treatment choices change significantly
• Hair loss plus acne, irregular periods, weight changes, fatigue, or cold intolerance, where a broader workup is needed

What this article doesn’t cover

We’ve focused on the common adult-onset presentation of FPHL. We’ve left out the management of FPHL specifically in pregnancy and breastfeeding (where most treatments are contraindicated), FPHL in adolescents (which has its own diagnostic considerations), and the cosmetic camouflage options that many women find useful while waiting for treatment to take effect. Hair transplants for women are also a distinct topic with different selection criteria than for men.

The social and emotional weight of FPHL is real, and it’s not your imagination that the wider culture treats women’s hair loss differently than men’s. If it’s affecting your wellbeing, talk to a GP or dermatologist, and consider a peer community. The isolation around women’s hair loss is itself part of why it’s hard. You’re not alone in finding it hard.